As per the pre-agreed terms of the JV, Bayer has secured full ownership of the entity which was formed for the sales and marketing of pharmaceutical products in the Indian market


Bayer concludes the Bayer Zydus Pharma JV with Zydus Lifesciences. (Credit: Bayer AG)

Bayer Pharmaceuticals has taken full ownership of Bayer Zydus Pharma (BZPPL) by acquiring the remaining 25% from its joint venture (JV) partner Zydus Lifesciences (formerly Cadila Healthcare).

The joint venture was established in January 2011 for the sales and marketing of pharmaceutical products in the Indian market with both parties having a stake of 50% each. In 2018, Bayer Pharmaceuticals increased its stake in the JV to 75%.

In 2021, Bayer Pharmaceuticals and Zydus Lifesciences extended the JV by three years.

The JV used the capabilities of both companies to enhance their offerings in the growing Indian market.

It combined Zydus Lifesciences’ Indian marketing and sales expertise, distribution network, and industry connections with the global expertise of Bayer Pharmaceuticals in commercialising novel products.

Bayer Zydus Pharma is claimed to have achieved notable advancements across multiple therapeutic areas, including cardiovascular diseases, diabetes, women’s health, ophthalmology, and oncology.

The JV company introduced several of Bayer Pharmaceuticals’  global assets, such as Xarelto, Eylea, and Visanne in India.

Bayer pharmaceuticals division India managing director and South Asia country division head Shweta Rai said: “Zydus Lifesciences has been a formidable partner in our joint mission towards introducing best-in-class innovative health solutions and addressing the unmet healthcare needs of patients in India.

“As we assume full ownership of BZPPL, Bayer remains committed to ensuring its steadfast presence in India. Building on the gains made over more than a decade, we aim to carry forward our mission of ‘Health for All, Hunger for None’.”

In March, Bayer acquired the rights to commercialise BridgeBio’s oral transthyretin (TTR) stabiliser Acoramidis in Europe, for up to $310m. Acoramidis is an investigational, next-generation, orally administered, highly potent, and selective small molecule TTR stabiliser.